scholarly journals PIN84 - THE STUDY OF THE CONSUMPTION OF ANTIVIRAL DRUGS USED FOR PHARMACOTHERAPY IN PATIENTS WITH ACUTE RESPIRATORY VIRAL INFECTIONS IN UKRAINE

2018 ◽  
Vol 21 ◽  
pp. S235
Author(s):  
L. Iakovlieva ◽  
O. Tkachova ◽  
O. Berdnik ◽  
O. Gerasymova ◽  
N. Bezditko ◽  
...  
Keyword(s):  
Viral Infections ◽  
Antiviral Drugs ◽  
Respiratory Viral Infections

scholarly journals Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections

2018 ◽  
Vol 99 (2) ◽  
pp. 215-223 ◽  
Author(s):  
E P Tikhonova ◽  
T Yu Kuz'mina ◽  
N V Andronova ◽  
O A Tyushevskaya ◽  
T A Elistratova ◽  
...  
Keyword(s):  
Antiviral Therapy ◽  
Clinical Efficacy ◽  
Viral Infections ◽  
Clinical Symptoms ◽  
Antiviral Drug ◽  
Antiviral Drugs ◽  
Control Group ◽  
Efficacy And Safety ◽  
Respiratory Viral Infections ◽  
Adaptive Reactions

Aim. Comparative study of clinical efficacy and safety of antiviral drug triazavirin and umifenovir in the treatment of patients with acute respiratory viral infections and influenza. Methods. The study included 100 patients aged 18 to 65 years diagnosed with moderate acute respiratory viral infection. Group 1 included 34 patients receiving umifenovir 200 mg 4 times a day for 5 days, and comparison group included 32 patients who received triazavirin 1 capsule (250 mg) 3 times a day for 5 days. Group 3 (control group) included 34 patients not treated with antiviral therapy. Efficacy and safety of the studied antiviral drugs were evaluated based on clinical symptoms in the disease course and were confirmed by adaptive reactions of the organism. Results. Among patients receiving triazavirin, recovery time and fever, headache and catarrhal syndrome resolution time were less than among patients who received umifenovir. On triazavirin treatment with favorable tolerability, symptomatic medications (antipyretics) were discontinued, and the duration of their use was less, than in patients receiving umifenovir. Evaluation of clinical efficacy of umifenovir and triazavirin for the treatment of acute respiratory viral infections and influenza demonstrated that the drugs effectively reverse the main symptoms of the disease (p <0.05), reduce complications incidence (18.1±2.1% vs. 55.9±3.2%, p <0.05) and contribute to the stabilization of adaptive reactions of the organism in contrast to the results of patients not receiving etiotropic therapy (6.9±2.9% vs. 12.8±2.7, p <0.05). During the use of umifenovir by day 4 and during the use of triazavirin by day 3 intoxication and catarrhal syndromes had been reversed, while in case of the absence of antiviral therapy, 55.8% of patients had continuing intoxication and catarrhal symptoms. Conclusion. The results of the study allow defining umifenovir and triazavirin as the first line of defense against acute respiratory viral infections with good efficacy and tolerability of the drugs.

scholarly journals Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia

2019 ◽  
Vol 91 (11) ◽  
pp. 105-109
Author(s):  
N Y Pshenichnaya ◽  
V A Bulgakova ◽  
E V Volchkova ◽  
E N Kareva ◽  
E P Selkova ◽  
...  
Keyword(s):  
Influenza A ◽  
Viral Infections ◽  
Laboratory Data ◽  
Antiviral Drugs ◽  
Immunomodulatory Activity ◽  
Influenza A Viruses ◽  
Future Directions ◽  
Repeated Use ◽  
Combined Action ◽  
Respiratory Viral Infections

Aim: to determine the perspectives for the use of drugs with combined antiviral, anti - inflammatory and immunomodulatory activity on the basis of medical studies of existing antiviral drugs for the treatment of influenza and acute respiratory viral infections in Russia. Materials and methods. A brief review of the antiviral drugs used in Russia for the treatment of influenza and acute respiratory viral infections was conducted on the basis of 37 articles published in Scopus, Web of Science (WoS), and RSCI databases in the period from 1997 to 2018. Results. Resistance to neuraminidase inhibitors (oseltamivir, zanamivir), is slowly developing due to the mutations of the neuraminidase gene H275Y and Q136K. Most influenza A viruses remain resistant to adamantane antivirals. Repeated use of immunomodulators with indirect antiviral action leads to a hyporeactivity of the immune system and, subsequently, to a decrease in their effectiveness. Positive clinical and laboratory data in clinical trials were obtained using Enisamium iodide, a drug with combined action - direct antiviral, and immunomodulatory. Conclusion. According to the WHO strategy, the results of the review demonstrate the need for continued research of medications with combined antiviral and pathogenetic effects on the infectious process caused by influenza and acute respiratory viral infections.

scholarly journals EFFICACY OF KAGOCEL IN NONSPECIFIC PREVENTION OF ACUTE RESPIRATORY VIRAL INFECTIONS AND INFLUENZA

2019 ◽  
Vol 5 (3) ◽  
pp. 68-76
Author(s):  
Irina V. Ozerova ◽  
Nikolay A. Malishev
Keyword(s):  
Immune Response ◽  
Viral Infections ◽  
Respiratory Infections ◽  
Antiviral Drug ◽  
Economic Cost ◽  
Antiviral Drugs ◽  
High Risk Group ◽  
Time Data ◽  
Direct Acting Antiviral ◽  
Respiratory Viral Infections

Acute respiratory viral infections (ARVI) are some of the most widely spread diseases worldwide that are of 80% of economic cost of infectious diseases. It is known that specific prophylaxis (vaccination) and, in some clinical cases, direct-acting antiviral prophylaxis are key strategies for the prevention of influenza as one of the most dangerous ARVI viruses. However, there are a number of reasons why specific prophylaxis of influenza does not entirely address the issue of prophylaxis of ARVI that are caused by more than 200 different viruses, such as formation of immune response only to vaccine influenza strains and absence of immune response to other respiratory infections, induction in the case of short-term protection, especially, in the aged and others. Prevention of influenza with antiviral drugs is limited by risks of development of resistant influenza strains aa well as contraindications and limitations of use. Therefore, the use of nonspecific drugs such as broad-spectrum antiviral drugs of interferon type (IFN) and their inducers (II), as well as sanitary and hygienic measures is recommended for prevention. For the purpose of prevention, the use of inducers of endogenic interferons is relevant in unvaccinated persons during pre-epidemic and epidemic ARVI periods; in high-risk group (students, medical professions, transport workers, elderly, patients with comorbid pathologies, people in structured organizations, for example, military personnel), in immunocompromised people. One of the most extensively studied interferon inducers widely used in clinical practice since 2003 for prevention and treatment of influenza and diseases caused by Herpesviruses is an antiviral drug Kagocel®. The paper presents real-time data of the preventive efficacy of Kagocel® in the therapy of acute respiratory viral infections and influenza caused by different viral strains including pandemic ones.

Chemokines in Respiratory Viral Infections: Focus on Their Diagnostic and Therapeutic Potential

2011 ◽  
Vol 31 (4) ◽  
pp. 341-356 ◽  
Author(s):  
Virginia Amanatidou ◽  
Apostolos Zaravinos ◽  
Stavros Apostolakis ◽  
Demetrios A. Spandidos
Keyword(s):  
Viral Infections ◽  
Therapeutic Potential ◽  
Respiratory Viral Infections

SYNDROME OF SYSTEMIC INFLAMMATORY RESPONSE IN PATIENTS WITH ACUTE RESPIRATORY VIRAL INFECTIONS OF CHILDREN

2017 ◽  
Vol 96 (4) ◽  
pp. 22-27 ◽  
Author(s):  
I. V. Babachenko ◽  
◽  
L. A. Alekseeva ◽  
O. M. Ibragimova ◽  
Т. V. Bessonova ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Viral Infections ◽  
Systemic Inflammatory Response ◽  
Respiratory Viral Infections

Nucleosides and Nucleoside Analogues as Emerging Antiviral Drugs

2020 ◽  
Vol 17 ◽  
Author(s):  
Mohamed Ibrahim Elzagheid
Keyword(s):  
Significant Role ◽  
Mode Of Action ◽  
Crucial Role ◽  
Viral Infections ◽  
Antiviral Drugs ◽  
Review Article ◽  
Nucleoside Analogues ◽  
The Past ◽  
Nucleoside Drugs

: Nucleosides and their analogues have been in use for many years and have become essential for treating patients with viral infections. Many additional nucleoside drugs have been approved over the past decades. This strongly demonstrates how important these compounds are and the crucial role they play. Given that a significant amount of research and literature has been documented regarding nucleoside analogues, this review article mainly focuses the discussion on nucleosides and nucleoside analogous that have proven to play significant role or be emerging in the treatment of known viral infections. This covers the names, structures, applications, toxicity, and mode of action of relevant nucleoside analogues.

Sign in / Sign up

Export Citation Format

Share Document